Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 6,472 | 35,538 | 5,175 | 19,223 | 14,745 |
| Cost of Goods | 12,490 | 14,276 | 14,687 | 20,161 | 21,829 |
| Gross Profit | -6,018 | 21,262 | -9,512 | -938 | -7,084 |
| Operating Expenses | 122,977 | 129,873 | 163,377 | 175,450 | 185,113 |
| Operating Income | -128,505 | -108,335 | -172,202 | -176,227 | -191,368 |
| Other Income | 6,397 | 232 | 9,952 | 4,330 | -11,277 |
| Pre-tax Income | -122,108 | -108,103 | -162,250 | -171,897 | -202,645 |
| Income Tax | -4,604 | 19 | 3 | 0 | -158 |
| Net Income Continuous | -117,504 | -108,122 | -162,253 | -171,897 | -202,487 |
| Net Income | $-117,504 | $-108,122 | $-162,253 | $-171,897 | $-202,487 |
| EPS Basic Total Ops | -0.22 | -0.17 | -0.36 | -0.41 | -0.50 |
| EPS Basic Continuous Ops | -0.22 | -0.16 | -0.36 | -0.41 | -0.50 |
| EPS Diluted Total Ops | -0.22 | -0.17 | -0.36 | -0.41 | -0.50 |
| EPS Diluted Continuous Ops | -0.22 | -0.16 | -0.36 | -0.41 | -0.50 |
| EPS Diluted Before Non-Recurring Items | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 |
| EBITDA(a) | $-108,832 | $-88,857 | $-151,159 | $-152,378 | $-172,037 |